Palisade Bio (NASDAQ: PALI) net income
Palisade Bio reported a net loss of $16.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $14.4m. Earnings per share were −$0.30.
Palisade Bio's best year of the last 10 was fiscal 2018. It reported a loss in 10 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$16.8m | — | — | −$0.30 |
| 2024 | −$14.4m | — | — | −$10.19 |
| 2023 | −$12.3m | — | −4,100.0% | −$1.80 |
| 2022 | −$14.3m | — | — | −$16.53 |
| 2021 | −$26.6m | — | — | −$2.86 |
| 2020 | −$10.3m | — | −76,346.2% | −$3.72 |
| 2019 | −$8.4m | — | −54,252.6% | — |
| 2018 | −$4.9m | — | −1,894.1% | — |
| 2017 | −$15.7m | — | −6,025.4% | — |
| 2016 | −$21.1m | — | −129,721.8% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Palisade Bio net income compared with its sector
By net income for its latest fiscal year, Palisade Bio ranks 201st of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 199th | Axogen | −$15.7m | −7.0% |
| 200th | Arcutis Biotherapeutics | −$16.1m | −4.3% |
| 201st | Palisade Bio | −$16.8m | — |
| 202nd | Alpha Teknova | −$17.3m | −42.6% |
| 203rd | CytomX Therapeutics | −$17.4m | −22.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Palisade Bio
- How much did Palisade Bio earn in fiscal 2025?
- Palisade Bio reported a net loss of $16.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $14.4m.
- What are the earnings per share of Palisade Bio?
- They were −$0.30 in fiscal 2025, compared with −$10.19 in fiscal 2024.
- Where does Palisade Bio rank in its sector by net income?
- It ranks 201st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Palisade Bio come from?
- From the annual report (Form 10-K) that Palisade Bio files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Palisade Bio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Palisade Bio: the Palisade Bio page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.